دورية أكاديمية
أعرض في EDS

Nutritional Sensor REDD1 in Cancer and Inflammation: Friend or Foe?

التفاصيل البيبلوغرافية
العنوان: Nutritional Sensor REDD1 in Cancer and Inflammation: Friend or Foe?
المؤلفون: Zhidkova EM; Department of Chemical Carcinogenesis, N.N. Blokhin NMRCO, 115478 Moscow, Russia., Lylova ES; Department of Chemical Carcinogenesis, N.N. Blokhin NMRCO, 115478 Moscow, Russia., Grigoreva DD; Department of Chemical Carcinogenesis, N.N. Blokhin NMRCO, 115478 Moscow, Russia., Kirsanov KI; Department of Chemical Carcinogenesis, N.N. Blokhin NMRCO, 115478 Moscow, Russia.; Faculty of General Medical Practice, Russian University of People's Friendship (RUDN), 117198 Moscow, Russia., Osipova AV; Department of Chemical Carcinogenesis, N.N. Blokhin NMRCO, 115478 Moscow, Russia., Kulikov EP; Faculty of Oncology, I.P. Pavlov Ryazan State Medical University, 390026 Ryazan, Russia., Mertsalov SA; Faculty of Oncology, I.P. Pavlov Ryazan State Medical University, 390026 Ryazan, Russia., Belitsky GA; Department of Chemical Carcinogenesis, N.N. Blokhin NMRCO, 115478 Moscow, Russia., Budunova I; Department of Dermatology, Northwestern University, Chicago, IL 60611, USA., Yakubovskaya MG; Department of Chemical Carcinogenesis, N.N. Blokhin NMRCO, 115478 Moscow, Russia., Lesovaya EA; Department of Chemical Carcinogenesis, N.N. Blokhin NMRCO, 115478 Moscow, Russia.; Faculty of Oncology, I.P. Pavlov Ryazan State Medical University, 390026 Ryazan, Russia.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2022 Aug 26; Vol. 23 (17). Date of Electronic Publication: 2022 Aug 26.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Glucocorticoids*/pharmacology , Neoplasms*/genetics, Transcription Factors/*metabolism, Humans ; Inflammation ; Receptors, Glucocorticoid/metabolism ; Signal Transduction
مستخلص: Regulated in Development and DNA Damage Response 1 (REDD1)/DNA Damage-Induced Transcript 4 (DDIT4) is an immediate early response gene activated by different stress conditions, including growth factor depletion, hypoxia, DNA damage, and stress hormones, i.e., glucocorticoids. The most known functions of REDD1 are the inhibition of proliferative signaling and the regulation of metabolism via the repression of the central regulator of these processes, the mammalian target of rapamycin (mTOR). The involvement of REDD1 in cell growth, apoptosis, metabolism, and oxidative stress implies its role in various pathological conditions, including cancer and inflammatory diseases. Recently, REDD1 was identified as one of the central genes mechanistically involved in undesirable atrophic effects induced by chronic topical and systemic glucocorticoids widely used for the treatment of blood cancer and inflammatory diseases. In this review, we discuss the role of REDD1 in the regulation of cell signaling and processes in normal and cancer cells, its involvement in the pathogenesis of different diseases, and the approach to safer glucocorticoid receptor (GR)-targeted therapies via a combination of glucocorticoids and REDD1 inhibitors to decrease the adverse atrophogenic effects of these steroids.
Competing Interests: The authors declare no conflict of interest.
References: Cell Metab. 2016 Nov 8;24(5):653-654. (PMID: 27829135)
J Immunol. 2021 Oct 1;207(7):1747-1754. (PMID: 34452931)
Cell Metab. 2011 Feb 2;13(2):170-82. (PMID: 21284984)
Mol Cancer Ther. 2020 Sep;19(9):1898-1908. (PMID: 32546661)
Inflamm Res. 2020 Apr;69(4):365-373. (PMID: 32130427)
Sci Rep. 2017 Aug 1;7(1):7023. (PMID: 28765650)
Autophagy. 2016 May 3;12(5):898-9. (PMID: 27129029)
Genes Dev. 2004 Dec 1;18(23):2893-904. (PMID: 15545625)
EBioMedicine. 2019 Mar;41:526-537. (PMID: 30737086)
Biomolecules. 2022 Apr 14;12(4):. (PMID: 35454171)
J Biol Chem. 1994 Jul 8;269(27):17971-80. (PMID: 8027056)
Exp Mol Med. 2021 Oct;53(10):1612-1622. (PMID: 34697389)
Cell. 2019 Oct 31;179(4):813-827. (PMID: 31675495)
Cell Metab. 2016 Jan 12;23(1):27-47. (PMID: 26771115)
J Virol. 2018 Aug 16;92(17):. (PMID: 29925665)
Endocr Rev. 2003 Aug;24(4):488-522. (PMID: 12920152)
Cell. 2012 Apr 13;149(2):274-93. (PMID: 22500797)
Immunol Rev. 2012 Sep;249(1):43-58. (PMID: 22889214)
Sci Rep. 2017 May 8;7(1):1526. (PMID: 28484222)
J Immunol. 2018 Mar 1;200(5):1618-1626. (PMID: 29378913)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Front Oncol. 2018 Apr 12;8:106. (PMID: 29707520)
Trends Endocrinol Metab. 2016 Dec;27(12):868-880. (PMID: 27613400)
Am J Physiol Endocrinol Metab. 2014 Dec 1;307(11):E983-93. (PMID: 25315696)
Mol Cell Biol. 2013 May;33(9):1711-22. (PMID: 23428870)
Int J Cancer. 2015 May 15;136(10):2341-51. (PMID: 25359525)
Nature. 2009 Jul 2;460(7251):108-12. (PMID: 19543266)
J Invest Dermatol. 2020 Sep;140(9):1698-1705.e1. (PMID: 32032578)
Trends Pharmacol Sci. 2016 Jan;37(1):4-16. (PMID: 26603477)
Curr Opin Immunol. 2013 Jun;25(3):347-55. (PMID: 23722114)
Nat Chem Biol. 2011 Sep 11;7(10):712-9. (PMID: 21909097)
Nat Med. 2010 Jul;16(7):767-73. (PMID: 20473305)
Cell Signal. 2016 May;28(5):412-424. (PMID: 26827808)
Exp Dermatol. 2006 Jun;15(6):406-20. (PMID: 16689857)
Oncol Lett. 2020 Jan;19(1):431-441. (PMID: 31897156)
Oncogene. 2005 Feb 10;24(7):1138-49. (PMID: 15592522)
Oncotarget. 2015 Oct 13;6(31):30730-44. (PMID: 26436695)
J Mol Endocrinol. 2018 Jul;61(1):R75-R90. (PMID: 29588427)
BMB Rep. 2021 Sep;54(9):470-475. (PMID: 34488932)
Am J Physiol Cell Physiol. 2020 Nov 1;319(5):C807-C824. (PMID: 32877205)
EMBO Mol Med. 2014 Dec 11;7(1):42-58. (PMID: 25504525)
Genes Dev. 2020 Jun 1;34(11-12):751-766. (PMID: 32273287)
Nature. 2006 Mar 9;440(7081):228-32. (PMID: 16407890)
PLoS One. 2015 Aug 24;10(8):e0136323. (PMID: 26301899)
J Invest Dermatol. 2018 Sep;138(9):1935-1944. (PMID: 29596905)
Nature. 2008 Jul 24;454(7203):428-35. (PMID: 18650913)
Cancer Sci. 2019 Aug;110(8):2368-2377. (PMID: 31222863)
Endocrinology. 2010 Mar;151(3):1050-9. (PMID: 20032058)
Am J Pathol. 2014 Sep;184(9):2382-9. (PMID: 25016184)
Curr Rheumatol Rep. 2022 Jan;24(1):1-11. (PMID: 35150412)
PLoS One. 2012;7(12):e52154. (PMID: 23272222)
Oncotarget. 2020 Jan 28;11(4):409-418. (PMID: 32064044)
Biochem Biophys Res Commun. 2014 Oct 31;453(4):778-83. (PMID: 25445588)
Biomed Pharmacother. 2018 Aug;104:622-628. (PMID: 29803175)
Cancer Cell. 2013 Dec 9;24(6):695-709. (PMID: 24332039)
J Biol Chem. 2011 Aug 26;286(34):30181-9. (PMID: 21733849)
Cell Rep. 2017 Feb 14;18(7):1699-1712. (PMID: 28199842)
Bone. 2016 Dec;93:43-54. (PMID: 27596806)
Cancer Commun (Lond). 2018 Jul 5;38(1):45. (PMID: 29976242)
Ann Rheum Dis. 2019 Feb;78(2):238-248. (PMID: 30563869)
Cancer Res. 2012 Apr 1;72(7):1773-83. (PMID: 22447568)
Mol Cell Oncol. 2016 Sep 30;3(6):e1240549. (PMID: 28090580)
Cancer Res. 2011 Jul 1;71(13):4366-72. (PMID: 21540236)
Mol Cell Endocrinol. 2007 Sep 15;275(1-2):98-108. (PMID: 17587493)
Genes Dev. 2020 Dec 1;34(23-24):1565-1576. (PMID: 33262144)
J Biol Chem. 2003 Jul 18;278(29):27053-8. (PMID: 12736248)
NPJ Genom Med. 2016 Feb 03;1:15015. (PMID: 29263808)
Cell Cycle. 2009 Mar 1;8(5):780-6. (PMID: 19221489)
Breast Cancer (Auckl). 2020 Dec 20;14:1178223420974667. (PMID: 33424228)
J Allergy Clin Immunol. 2013 Nov;132(5):1033-44. (PMID: 24084075)
J Appl Physiol (1985). 2014 Aug 1;117(3):246-56. (PMID: 24876363)
Cell. 2004 Jul 23;118(2):229-41. (PMID: 15260992)
J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):417-432. (PMID: 29230965)
Cell Death Dis. 2021 Jun 26;12(7):652. (PMID: 34175899)
Mol Cell Endocrinol. 2016 Feb 15;422:64-73. (PMID: 26607805)
Proc Natl Acad Sci U S A. 2017 Feb 7;114(6):E990-E998. (PMID: 28115701)
Front Physiol. 2021 Nov 26;12:729713. (PMID: 34899373)
J Immunol. 2018 Jun 15;200(12):3950-3961. (PMID: 29712770)
Mol Cell Biol. 2005 Jul;25(14):5834-45. (PMID: 15988001)
BMC Genomics. 2013 Nov 05;14:758. (PMID: 24191950)
Cell Death Dis. 2016 Oct 27;7(10):e2434. (PMID: 27787518)
Pediatr Res. 2009 May;65(5):514-9. (PMID: 19127203)
Cell Cycle. 2005 Nov;4(11):1500-02. (PMID: 16258273)
Mol Cancer Res. 2014 Jun;12(6):867-77. (PMID: 24615339)
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7. (PMID: 27141961)
Adv Exp Med Biol. 2015;872:315-33. (PMID: 26216001)
Genes Dev. 2004 Dec 1;18(23):2879-92. (PMID: 15545626)
Handb Exp Pharmacol. 2017;237:171-196. (PMID: 27864677)
J Biol Chem. 2006 Dec 22;281(51):39128-34. (PMID: 17074751)
Curr Opin Pharmacol. 2010 Aug;10(4):497-504. (PMID: 20493772)
Nat Commun. 2015 Apr 28;6:7014. (PMID: 25916556)
Aging Cell. 2020 Dec;19(12):e13270. (PMID: 33166065)
Cell Metab. 2016 Nov 8;24(5):701-715. (PMID: 27773694)
Int J Clin Exp Pathol. 2014 Aug 15;7(9):5940-9. (PMID: 25337238)
Obesity (Silver Spring). 2009 Aug;17(8):1563-73. (PMID: 19265796)
Cancer Discov. 2022 Jan;12(1):31-46. (PMID: 35022204)
Diagn Pathol. 2018 Nov 14;13(1):87. (PMID: 30428884)
BMC Biol. 2018 Jun 12;16(1):65. (PMID: 29895328)
Clin Sci (Lond). 1998 Jun;94(6):557-72. (PMID: 9854452)
PLoS One. 2015 Apr 13;10(4):e0123721. (PMID: 25867026)
J Appl Physiol (1985). 2021 Dec 1;131(6):1718-1730. (PMID: 34672766)
Clin Cancer Res. 2018 Jan 15;24(2):445-459. (PMID: 29084921)
Cell Death Dis. 2019 Mar 7;10(3):227. (PMID: 30846680)
Proc Natl Acad Sci U S A. 2010 Mar 9;107(10):4675-80. (PMID: 20176937)
Anticancer Res. 2013 Sep;33(9):3807-14. (PMID: 24023313)
Trends Cancer. 2020 Oct;6(10):838-857. (PMID: 32482536)
Cancer Med. 2014 Apr;3(2):252-64. (PMID: 24515947)
Biochemistry. 2010 Mar 23;49(11):2491-501. (PMID: 20166753)
Am J Physiol Cell Physiol. 2019 Jan 1;316(1):C104-C110. (PMID: 30485138)
Mol Cell. 2002 Nov;10(5):995-1005. (PMID: 12453409)
Cell Cycle. 2009 Mar 1;8(5):675-6. (PMID: 19242117)
J Neurosci. 2011 Mar 2;31(9):3186-96. (PMID: 21368030)
Genes Cancer. 2011 Dec;2(12):1117-33. (PMID: 22866203)
Mol Cell Endocrinol. 2013 Jan 30;365(2):174-86. (PMID: 23116773)
Tumour Biol. 2011 Oct;32(5):893-904. (PMID: 21598042)
FASEB J. 2018 Aug;32(8):4585-4599. (PMID: 29547704)
Rheum Dis Clin North Am. 2016 Feb;42(1):15-31, vii. (PMID: 26611548)
Biochem Biophys Res Commun. 2022 Aug 6;616:56-62. (PMID: 35636256)
Mol Cell Biol. 2002 Apr;22(7):2283-93. (PMID: 11884613)
معلومات مُعتمدة: 17-75-20124 Russian Science Foundation
فهرسة مساهمة: Keywords: REDD1; cancer; combination therapy; glucocorticoids; inflammation; mTOR; metabolism
المشرفين على المادة: 0 (DDIT4 protein, human)
0 (Glucocorticoids)
0 (Receptors, Glucocorticoid)
0 (Transcription Factors)
تواريخ الأحداث: Date Created: 20220909 Date Completed: 20220912 Latest Revision: 20220922
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9456073
DOI: 10.3390/ijms23179686
PMID: 36077083
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms23179686